Verona Pharma (VRNA) News Today $66.51 +2.32 (+3.62%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Verona Pharma (VRNA) Projected to Post Earnings on ThursdayVerona Pharma (NASDAQ:VRNA) will be releasing earnings before the market opens on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666222)February 21 at 1:49 AM | marketbeat.comJacobson & Schmitt Advisors LLC Takes $2.03 Million Position in Verona Pharma plc (NASDAQ:VRNA)Jacobson & Schmitt Advisors LLC acquired a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 43,748 shares of the compaFebruary 20 at 5:49 AM | marketbeat.comVerona Pharma (NASDAQ:VRNA) Hits New 52-Week High - Still a Buy?Verona Pharma (NASDAQ:VRNA) Hits New 52-Week High - Still a Buy?February 19 at 8:47 PM | marketbeat.comRice Hall James & Associates LLC Sells 30,460 Shares of Verona Pharma plc (NASDAQ:VRNA)Rice Hall James & Associates LLC reduced its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 954,616 shares of the companyFebruary 18 at 6:49 AM | marketbeat.comVerona Pharma Announces March 2025 Investor Conference ParticipationFebruary 18 at 6:00 AM | globenewswire.comAlphaCentric Advisors LLC Sells 33,789 Shares of Verona Pharma plc (NASDAQ:VRNA)AlphaCentric Advisors LLC trimmed its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 67.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,211 shares of the company's stock after selling 33,789 shares dFebruary 17, 2025 | marketbeat.comChoreo LLC Acquires Shares of 4,893 Verona Pharma plc (NASDAQ:VRNA)Choreo LLC bought a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 4,893 shares of the company's stock, valued at approximately $230,000. SeveralFebruary 15, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Given New $72.00 Price Target at Canaccord Genuity GroupFebruary 15, 2025 | americanbankingnews.comVerona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate UpdateFebruary 13, 2025 | globenewswire.comLegato Capital Management LLC Purchases 14,183 Shares of Verona Pharma plc (NASDAQ:VRNA)Legato Capital Management LLC lifted its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 132.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,853 shares of the company's stock aFebruary 13, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High After Analyst UpgradeFebruary 13, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Sets New 12-Month High After Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Hits New 52-Week High After Analyst UpgradeFebruary 12, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $72.00Canaccord Genuity Group lifted their price target on shares of Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday.February 12, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Purchased by Values First Advisors Inc.Values First Advisors Inc. grew its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 36.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,505 shares of the company's stock after acquiring an additional 6,331 sharFebruary 12, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Reaches New 52-Week High - Here's What HappenedVerona Pharma (NASDAQ:VRNA) Sets New 12-Month High - Still a Buy?February 5, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)February 5, 2025 | markets.businessinsider.comVerona Pharma plc (NASDAQ:VRNA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Verona Pharma plc (NASDAQ:VRNA - Get Free Report) have been given an average recommendation of "Buy" by the eight ratings firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong bFebruary 5, 2025 | marketbeat.comMatisse Capital Has $669,000 Holdings in Verona Pharma plc (NASDAQ:VRNA)Matisse Capital cut its stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 38.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,400 shares of the company's stock after selling 9,000 shares during the period. MatisFebruary 4, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Holdings Raised by Jennison Associates LLCJennison Associates LLC increased its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 8.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,889,542 shares of the company's stock after purchaFebruary 4, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Price Up 5.3% - Here's WhyVerona Pharma (NASDAQ:VRNA) Trading 5.3% Higher - Should You Buy?February 3, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Short Interest UpdateVerona Pharma plc (NASDAQ:VRNA - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 8,220,000 shares, a growth of 19.1% from the December 31st total of 6,900,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is currently 7.1 days.February 1, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?Verona Pharma (NASDAQ:VRNA) Sets New 52-Week High - Here's WhyJanuary 30, 2025 | marketbeat.comMoody Aldrich Partners LLC Has $4.41 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)Moody Aldrich Partners LLC decreased its stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 62.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 94,942 shares of the company's stock afterJanuary 29, 2025 | marketbeat.comPFG Investments LLC Sells 7,100 Shares of Verona Pharma plc (NASDAQ:VRNA)PFG Investments LLC decreased its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 19.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,700 shares of the company's stock after selling 7,100 shares during the period. PFG InvestJanuary 28, 2025 | marketbeat.comShilanski & Associates Inc. Buys New Position in Verona Pharma plc (NASDAQ:VRNA)Shilanski & Associates Inc. purchased a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,576 shares of the company's stock, valued at apJanuary 24, 2025 | marketbeat.comQ1 EPS Estimates for Verona Pharma Lifted by HC WainwrightVerona Pharma plc (NASDAQ:VRNA - Free Report) - Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for Verona Pharma in a report released on Tuesday, January 21st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.24) per share forJanuary 23, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Hits New 1-Year High - Still a Buy?Verona Pharma (NASDAQ:VRNA) Reaches New 12-Month High - Here's What HappenedJanuary 22, 2025 | marketbeat.comVerona Pharma’s Ohtuvayre: Strong Performance and Growth Potential Drive Buy RatingJanuary 21, 2025 | markets.businessinsider.comVerona Pharma stock target upgraded, retains buy on Q4 resultsJanuary 21, 2025 | msn.comVerona Pharma price target raised to $60 from $42 at H.C. WainwrightJanuary 21, 2025 | markets.businessinsider.comIs Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?January 21, 2025 | msn.comAMI Asset Management Corp Sells 22,541 Shares of Verona Pharma plc (NASDAQ:VRNA)AMI Asset Management Corp cut its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 34.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,805 shares of the company's stock after selling 22,541 shares dJanuary 21, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Verona Pharma (NASDAQ:VRNA)HC Wainwright restated a "buy" rating and set a $60.00 price objective (up from $42.00) on shares of Verona Pharma in a report on Tuesday.January 21, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Price Down 3.1% - What's Next?Verona Pharma (NASDAQ:VRNA) Shares Down 3.1% - Here's WhyJanuary 17, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Reaches New 1-Year High - Time to Buy?Verona Pharma (NASDAQ:VRNA) Sets New 1-Year High - Still a Buy?January 16, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Has $9 Million Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)Hennion & Walsh Asset Management Inc. lifted its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 24.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 193,707 shares of the company's stock after acquiring an additional 37January 16, 2025 | marketbeat.comRecent High-Flyers: Top 10 Short-Term Picks That Skyrocketed!January 14, 2025 | markets.businessinsider.comVerona Pharma (NASDAQ:VRNA) Stock Price Up 4.5% - Should You Buy?Verona Pharma (NASDAQ:VRNA) Trading Up 4.5% - Still a Buy?January 13, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Upgraded to Strong-Buy at Roth CapitalRoth Capital upgraded Verona Pharma to a "strong-buy" rating in a report on Friday.January 11, 2025 | marketbeat.comRoth MKM Initiates Coverage of Verona Pharma plc - Depositary Receipt () (VRNA) with Buy RecommendationJanuary 11, 2025 | msn.comVerona Pharma plc (NASDAQ:VRNA) Given Consensus Recommendation of "Buy" by BrokeragesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target amJanuary 11, 2025 | marketbeat.comAnalysts Expect Breakeven For Verona Pharma plc (NASDAQ:VRNA) Before LongJanuary 11, 2025 | finance.yahoo.comVerona Pharma (NASDAQ:VRNA) Now Covered by Roth MkmRoth Mkm began coverage on shares of Verona Pharma in a report on Friday. They issued a "buy" rating and a $68.00 price target for the company.January 10, 2025 | marketbeat.comVerona Pharma price target raised to $77 from $51 at BTIGJanuary 9, 2025 | markets.businessinsider.comWells Fargo Sticks to Their Buy Rating for Verona Pharma (VRNA)January 8, 2025 | markets.businessinsider.comWells Fargo & Company Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) StockWells Fargo & Company raised their price target on Verona Pharma from $64.00 to $74.00 and gave the company an "overweight" rating in a report on Wednesday.January 8, 2025 | marketbeat.comVerona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be LimitedJanuary 8, 2025 | seekingalpha.comVerona Pharma (NASDAQ:VRNA) Given Buy Rating at Truist FinancialTruist Financial reissued a "buy" rating and issued a $57.00 price objective (up from $44.00) on shares of Verona Pharma in a research note on Wednesday.January 8, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High - Still a Buy?Verona Pharma (NASDAQ:VRNA) Hits New 1-Year High - Here's What HappenedJanuary 8, 2025 | marketbeat.comVerona Pharma sees Q4 net product sales revenue $36M vs. $0M a year agoJanuary 7, 2025 | markets.businessinsider.com Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Media Mentions By Week VRNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRNA News Sentiment▼0.880.60▲Average Medical News Sentiment VRNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRNA Articles This Week▼85▲VRNA Articles Average Week Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News SMMT News GMAB News ITCI News VTRS News MRNA News RDY News PCVX News SRPT News QGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRNA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRNA Stock Alerts